Absolute Quantitative Targeted Monitoring of Potential Plasma Protein Biomarkers: A Pilot Study on Healthy Individuals

• Published in: Biomedicines Vol. 12; no. 10; p. 2403
• Main Authors: Kononikhin, Alexey S, Starodubtseva, Natalia L, Brzhozovskiy, Alexander G, Tokareva, Alisa O, Kashirina, Daria N, Zakharova, Natalia V, Bugrova, Anna E, Indeykina, Maria I, Pastushkova, Liudmila Kh, Larina, Irina M, Mitkevich, Vladimir A, Makarov, Alexander A, Nikolaev, Evgeny N
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.10.2024; MDPI
• Subjects: Accuracy; Alzheimer's disease; Analysis; Apolipoproteins; BAK protein; Biological markers; Biomarkers; Blood; Blood coagulation; Blood proteins; Calibration; Cancer; Cardiovascular diseases; Communication; Development and progression; Diabetes; Diabetes mellitus; Drug approval; Ethnicity; Ethylenediaminetetraacetic acid; FDA approval; healthy volunteers; Immune system; Immunoglobulins; Mass spectrometry; Mass spectroscopy; Medical examination; MRM; Neurodegenerative diseases; Peptides; Physiological aspects; Plasma; Plasma proteins; Prevention; Proteins; Proteomics; Quality control; Quantitative analysis; Reproducibility; Risk factors; Russia; Canada; United States > US; proteomics; biomarkers; healthy volunteers; MRM; mass spectrometry; plasma; blood
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12102403

The development of blood tests for the early detection of individual predisposition to socially significant diseases remains a pressing issue. In this pilot study, multiple reaction monitoring mass spectrometry (MRM-MS) with a BAK-270 assay was applied for protein concentrations analysis in blood plasma from 21 healthy volunteers of the European cohort. The levels of 138 plasma proteins were reliably and precisely quantified in no less than 50% of samples. The quantified proteins included 66 FDA-approved markers of cardiovascular diseases (CVD), and other potential biomarkers of pathologies such as cancer, diabetes mellitus, and Alzheimer's disease. The analysis of individual variations of the plasma proteins revealed significant differences between the male (11) and female (10) groups. In total, fifteen proteins had a significantly different concentration in plasma; this included four proteins that exhibited changes greater than ±1.5-fold, three proteins (RBP4, APCS, and TTR) with higher levels in males, and one (SHBG) elevated in females. The obtained results demonstrated considerable agreement with the data collected from 20 samples of a North American cohort, which were analyzed with the similar MRM assay. The most significant differences between the cohorts of the two continents were observed in the level of 42 plasma proteins (including 24 FDA markers), of which 17 proteins showed a ≥1.5-fold change, and included proteins increased in North Americans (APOB, CRTAC1, C1QB, C1QC, C9, CRP, HP, IGHG1, IGKV4-1, SERPING1, RBP4, and AZGP1), as well as those elevated in Europeans (APOF, CD5L, HBG2, SELPLG, and TNA). The results suggest a different contribution of specific (patho)physiological pathways (e.g., immune system and blood coagulation) to the development of socially significant diseases in Europeans and North Americans, and they should be taken into account when refining diagnostic panels.